Advantage Alpha Capital Partners LP Invests $1.88 Million in Certara, Inc. (NASDAQ:CERT)

Advantage Alpha Capital Partners LP bought a new stake in Certara, Inc. (NASDAQ:CERT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 160,156 shares of the company’s stock, valued at approximately $1,875,000. Advantage Alpha Capital Partners LP owned approximately 0.10% of Certara as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in shares of Certara by 1.6% during the 1st quarter. Russell Investments Group Ltd. now owns 77,753 shares of the company’s stock worth $1,375,000 after buying an additional 1,191 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Certara by 6.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 58,899 shares of the company’s stock worth $1,054,000 after purchasing an additional 3,639 shares during the last quarter. Silvercrest Asset Management Group LLC raised its stake in shares of Certara by 27.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock worth $9,231,000 after purchasing an additional 110,636 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Certara by 2.9% during the 1st quarter. Janus Henderson Group PLC now owns 127,399 shares of the company’s stock worth $2,279,000 after purchasing an additional 3,578 shares in the last quarter. Finally, Motley Fool Asset Management LLC boosted its holdings in shares of Certara by 97.5% in the 1st quarter. Motley Fool Asset Management LLC now owns 98,566 shares of the company’s stock valued at $1,762,000 after buying an additional 48,671 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CERT. Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Finally, Barclays cut their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Certara has a consensus rating of “Hold” and an average target price of $15.92.

Insider Buying and Selling

In related news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This represents a 33.94 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Certara Stock Performance

NASDAQ CERT opened at $11.05 on Tuesday. The stock has a market cap of $1.78 billion, a PE ratio of -55.25, a P/E/G ratio of 5.24 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a 50-day moving average of $10.80 and a 200-day moving average of $13.13. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the business posted $0.06 earnings per share. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.